2 recruiting, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Unknown 1 |
Follow EGFR: new trials by email Literature Review of EGFR trials Research Report on EGFR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection TAS6417, Zipalertinib Matching-placebo - Lung Cancer, Adjuvant | Phase 3 | Recruiting | Taiho Oncology, Inc. | 360 | 2025-12-22 | 2026-10-13 |
| Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection - EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 300 | 2024-11-19 | 2026-08-13 |
| To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma Gefitinib, Vinorelbine, Carboplatin - NSCLC, EGFR | Phase 3 | Unknown | Shenzhen People's Hospital | 48 | 2018-08-31 | 2018-09-04 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Lung Neoplasms (1)
Carboplatin (2) · Cisplatin (1) · Gefitinib (1) · Injections (1) · Pemetrexed (1) · Vinorelbine (1) · zipalertinib (1)
Allist Pharmaceuticals, Inc. (1) · Shenzhen People's Hospital (1) · Taiho Oncology, Inc. (1)
China (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Italy (1) · Japan (1) · Malaysia (1) · Mexico (1) · Netherlands (1)
Qiu Chen, Doctor (1)
2025 (1)